Log in to search using one of your social media accounts:

 

Trastuzumab for 6 Months Instead of 1 Year? Trastuzumab for 6 Months Instead of 1 Year?
The standard of care for HER2-positive breast cancer is trastuzumab (Herceptin) for a year; but could half that be enough?Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 22, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Trastuzumab Emtansine in HER2 Metastatic Breast Cancer Trastuzumab Emtansine in HER2 Metastatic Breast Cancer
Recent survival results lead some to question the optimal sequence for trastuzumab emtansine in metastatic breast cancer.Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 21, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Shorter-Duration Trastuzumab as Effective for HER2+ Early Breast Cancer
Women with HER2-positive early breast cancer achieved similar disease-free survival with 6 months of adjuvant trastuzumab compared with a 12-month duration, according to the phase III PERSEPHONE trial. (Source: CancerNetwork)
Source: CancerNetwork - May 17, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASCO Breast Cancer HER2-Positive Breast Cancer SiteTerms/www.cannabissciencetech.com/News Source Type: news

Shorter trastuzumab treatment for HER2+ breast cancer can be as effective, with fewer cardiac side-effects
(American Society of Clinical Oncology) A phase III randomized clinical trial of 4,088 women with HER2-positive, early-stage breast cancer found that taking trastuzumab (Herceptin) for 6 months was non-inferior to the current standard of 12 months. The disease-free survival rate at four years was 89.4 percent with 6 months of therapy and 89.8 percent with 12 months of therapy. In addition, only 4 percent of women in the 6-month arm stopped trastuzumab early because of cardiac problems, compared with 8 percent in the 12-month arm. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 16, 2018 Category: International Medicine & Public Health Source Type: news

Targeting AXL Could Slow Metastasis in HER2-Positive Breast Cancer
New research has found that expression of AXL is correlated with poor outcomes in patients with HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 14, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer SiteTerms/www.cannabissciencetech.com/News Source Type: news

Lab Study Shows HER2 Inhibitor Lapatinib Can Induce Cell Proliferation
A laboratory study has found that the HER2 inhibitor lapatinib used to slow HER2-positive breast cancer can actually induce tumor growth in some circumstances. (Source: CancerNetwork)
Source: CancerNetwork - May 8, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer SiteTerms/www.cannabissciencetech.com/News Source Type: news

CHMP recommends EU approval of Roche ’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence
Roche today announced the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Perjeta® (pertuzumab) in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen) for post-surgery (adjuvant) treatment of adult patients with HER2-positive early breast c ancer (eBC) at high risk of recurrence. (Source: Roche Media News)
Source: Roche Media News - April 27, 2018 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche ’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence
Roche today announced the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Perjeta® (pertuzumab) in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen) for post-surgery (adjuvant) treatment of adult patients with HER2-positive early breast c ancer (eBC) at high risk of recurrence. (Source: Roche Investor Update)
Source: Roche Investor Update - April 27, 2018 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche ’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence
Roche today announced the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Perjeta® (pertuzumab) in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen) for post-surgery (adjuvant) treatment of adult patients with HER2-positive early breast c ancer (eBC) at high risk of recurrence. (Source: Roche Media News)
Source: Roche Media News - April 27, 2018 Category: Pharmaceuticals Source Type: news

New Drug Combo Ups Survival in HER2/neu Uterine Serous Cancer
WEDNESDAY, April 18, 2018 -- For patients with human epidermal growth factor receptor 2 (HER2)/neu-positive uterine serous carcinoma, adding intravenous trastuzumab to treatment with carboplatin-paclitaxel is associated with increased... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 18, 2018 Category: Pharmaceuticals Source Type: news

Delay to Formalin Fixation Effect on Breast Cancer Molecules Delay to Formalin Fixation Effect on Breast Cancer Molecules
What effect does delay to formalin fixation have on breast biomarkers such as ER, PR, HER2, Ki-67, and others? Might DFF be a confounding factor in breast biomarker assays?American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 17, 2018 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Trastuzumab Effective in Uterine Serous Carcinoma (CME/CE)
(MedPage Today) -- In patients overexpressing HER2, a 5-month boost in PFS when added to carboplatin-paclitaxel (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 14, 2018 Category: Hematology Source Type: news

HER2+ Breast Cancer Subtypes Resistant to TKIs Through Differing Mechanisms
Laboratory studies suggest that mechanisms of resistance to tyrosine kinase inhibitor therapy differ between the specific subtypes of HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - April 12, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer News Source Type: news

Some HER2+ Breast Cancer Patients Could Avoid SLNB Following Neoadjuvant Therapy
Two new studies have found that some HER2-positive and triple-negative breast cancer patients can avoid sentinel lymph node biopsy after neoadjuvant systemic therapy. (Source: CancerNetwork)
Source: CancerNetwork - April 2, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer News Triple-Negative Breast Cancer Source Type: news

Does Trastuzumab Plus Carbo/Paclitaxel Up PFS in Advanced HER2+ Uterine Carcinoma?
At SGO 2018, an early study showed ‘encouraging’ PFS with trastuzumab added to combination carboplatin/paclitaxel for advanced HER2/neu-overexpressing uterine serous carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - March 30, 2018 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Gynecologic Cancers News Conferences/SGO Source Type: news

Amgen And Allergan Receive Positive CHMP Opinion For ABP 980 (Biosimilar Herceptin(R)) For The Treatment Of Three Types Of Cancer
Recommended for Approval for the Same Indications as Herceptin® (Trastuzumab) Positive Opinion for ABP 980 is Supported by Phase 3 Data in Patients With HER2-Postive Early Breast Cancer THOUSAND OAKS, Calif., March 23, 2018 -- (Healthcare Sales &... Biopharmaceuticals, Oncology, Regulatory Amgen, Allergan, biosimilar, Herceptin, trastuzumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 23, 2018 Category: Pharmaceuticals Source Type: news

Caris Life Sciences Announces Published Results Showing that its ADAPT Biotargeting System Effectively Stratified Breast Cancer Patients Based on Their Benefit from Trastuzumab Treatment (Herceptin)
Data featured in Nature Communications showed ADAPT Biotargeting System significantly out-performed industry standard HER2 testing IRVING, Texas, March 23, 2018 -- (Healthcare Sales & Marketing Network) -- Caris Life Sciences®, a leading innovator ... Biopharmaceuticals, Diagnostics, Oncology Caris Life Sciences, ADAPT Biotargeting System, trastuzumab, Herceptin (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 23, 2018 Category: Pharmaceuticals Source Type: news

Amgen And Allergan Receive Positive CHMP Opinion For ABP 980 (Biosimilar Herceptin ®) For The Treatment Of Three Types Of Cancer
Recommended for Approval for the Same Indications as Herceptin® (Trastuzumab) Positive Opinion for ABP 980 is Supported by Phase 3 Data in Patients With HER2-Postive Early Breast Cancer THOUSAND OAKS, Calif., March 23, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the marketing authorization of ABP 980, a biosimilar to Herceptin® (trastuzumab). ABP 980 has been recommended for approval for the treatment of the same three types of...
Source: Amgen News Release - March 23, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

HER2 Is Not a Cancer Subtype but Rather a Pan-Cancer Event HER2 Is Not a Cancer Subtype but Rather a Pan-Cancer Event
Research in breast cancer genomics reveals the potential for combining anti-HER2 therapy with anti-androgen agents.Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 22, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Protecting Breast Cancer Patients From Cardiac Adverse Effects of Treatment With Anthracyclines and HER2-Targeted Therapies
During the 2018 Miami Breast Cancer Conference, cardiologist Dr. Jean-Bernard Durand discussed protecting patients who are being treated with anthracyclines and HER2-targeted therapies from serious cardiac adverse events. (Source: CancerNetwork)
Source: CancerNetwork - March 21, 2018 Category: Cancer & Oncology Authors: Jean-Bernard Durand, MD Tags: Conference Report Conferences/MBCC Source Type: news

Why Some Breast Cancer Becomes Resistant to Hormone Therapy Why Some Breast Cancer Becomes Resistant to Hormone Therapy
Acquired mutations in HER2 explain some of the resistance to hormone therapy seen in metastatic breast cancer; this unexpected finding offers a way to clinically manage these patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 20, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Management of Early-Stage HER2-Positive Breast Cancer
During the 2018 Miami Breast Cancer Conference, Dr. Sara Hurvitz discussed current management options for patients with early-stage HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - March 15, 2018 Category: Cancer & Oncology Authors: Sara Hurvitz, MD Tags: Conferences/MBCC News Source Type: news

Area surrounding a tumor impacts how breast cancer cells grow
(Oregon Health& Science University) A research team from Oregon Health& Science University, led by Joe Gray, Ph.D. and Jim Korkola, Ph.D. discover a tumor's 'microenvironment' plays a critical role in how HER2 positive breast cancer responds to treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 14, 2018 Category: International Medicine & Public Health Source Type: news

Lisinopril and Carvedilol Reduce Cardiotoxicity in HER2+ Breast Cancer
Lisinopril and carvedilol reduced cardiotoxicity in patients with HER2-positive breast cancer treated with trastuzumab and anthracyclines. (Source: CancerNetwork)
Source: CancerNetwork - March 13, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer News Source Type: news

Study: Two drugs prevent heart problems in breast cancer patients
(University of Kentucky) Data presented from a Late-Breaking Clinical Trial at the American College of Cardiology's 67th Annual Scientific Session Data demonstrated the effectiveness of beta blockers or ACE inhibitors to reduce the risk of cardio toxicity for HER2-positive breast cancer patients undergoing chemotherapy (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 11, 2018 Category: Cancer & Oncology Source Type: news

Early HER2+ Breast Cancer May Develop an Immunosuppressive Phenotype After Therapy
Some patients with HER2-positive breast cancer may develop an immunosuppressive phenotype based on an increase in regulatory T cells following treatment. (Source: CancerNetwork)
Source: CancerNetwork - March 9, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer News Source Type: news

Switching on survival signalling to drive drug resistance
(Queen Mary University of London) Researchers at Queen Mary University of London have discovered that the loss of a single protein- PHLDA1- is sufficient for the development of drug resistance to a type of targeted therapy in endometrial and HER2-positive breast cancer cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 27, 2018 Category: Cancer & Oncology Source Type: news

Dual HER2 Blockade/Chemo Improves Outcomes in Older Breast Cancer Patients
The addition of metronomic chemotherapy to dual HER2 blockade improved outcomes in older and frail patients with HER2-positive metastatic breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - February 20, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer News Source Type: news

Beyond APHINITY: What Now After Pivotal Breast Cancer Trial? Beyond APHINITY: What Now After Pivotal Breast Cancer Trial?
Dr Kathy Miller speaks with APHINITY's principal investigator about whether survival in HER2+ disease can be pushed even further.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 15, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

' Soft' Chemo Plus Targeted Therapy Works in HER2 Breast Cancer (CME/CE)
(MedPage Today) -- Combo increased PFS in older patients and had an acceptable safety profile (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - February 9, 2018 Category: OBGYN Source Type: news

Soft chemotherapy is very effective in older patients when added to targeted treatment in an aggressive breast cancer subtype
(European Organisation for Research and Treatment of Cancer) A trial published todayin The Lancet Oncology, shows that, in older patients with HER2 positive metastatic breast cancer (an aggressive breast cancer subtype where the cancer has spread to other parts of the body), a combination of a 'soft' chemotherapy with antiHER2 therapy is highly active and has low toxicity, important in a frail population. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - February 9, 2018 Category: International Medicine & Public Health Source Type: news

Trastuzumab Biosimilar Equivalent in Early HER2+ Breast CA Tx (CME/CE)
(MedPage Today) -- Ratio of breast pathologic complete response rate 10% higher with SB3 (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 7, 2018 Category: Hematology Source Type: news

SILAC identifies LAD1 as a filamin-binding regulator of actin dynamics in response to EGF and a marker of aggressive breast tumors
Mutations mimicking growth factor–induced proliferation and motility characterize aggressive subtypes of mammary tumors. To unravel currently unknown players in these processes, we performed phosphoproteomic analysis on untransformed mammary epithelial cells (MCF10A) that were stimulated in culture with epidermal growth factor (EGF). We identified ladinin-1 (LAD1), a largely uncharacterized protein to date, as a phosphorylation-regulated mediator of the EGF-to-ERK pathway. Further experiments revealed that LAD1 mediated the proliferation and migration of mammary cells. LAD1 was transcriptionally induced, phosphorylat...
Source: Signal Transduction Knowledge Environment - January 30, 2018 Category: Science Authors: Roth, L., Srivastava, S., Lindzen, M., Sas-Chen, A., Sheffer, M., Lauriola, M., Enuka, Y., Noronha, A., Mancini, M., Lavi, S., Tarcic, G., Pines, G., Nevo, N., Heyman, O., Ziv, T., Rueda, O. M., Gnocchi, D., Pikarski, E., Admon, A., Caldas, C., Yarden, Y. Tags: STKE Research Articles Source Type: news

Two Agents Offer Similar pCR Rates in ETNA Breast Cancer Trial (CME/CE)
(MedPage Today) -- Tumor subtype most significant factor for response among ERBB/HER2-negative patients (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 15, 2018 Category: Hematology Source Type: news

UC researchers find protein that mediates formation of HER2-driven breast cancer
(University of Cincinnati Academic Health Center) Researchers at the University of Cincinnati College of Medicine have identified for the first time that the estrogen receptor-binding protein MED1 is a critical mediator of HER2-driven breast cancer, identifying it as a potential therapeutic target. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 9, 2018 Category: Cancer & Oncology Source Type: news

Novartis Kisqali ® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer
Novartis today announced Kisqali® (ribociclib) received US Food and Drug Administration (FDA) Breakthrough Therapy designation for initial endocrine-based treatment of pre- or perimenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer in combination with tamoxifen or an aromatase inhibitor. (Source: World Pharma News)
Source: World Pharma News - January 3, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Trastuzumab: No negative impact on cardiac function
(NRG Oncology) Long-term follow-up results of the NRG Oncology trial NSABP B-31 have shown that the addition of trastuzumab to adjuvant chemotherapy does not negatively affect cardiac function in women with node-positive, human epidermal growth factor receptor 2 (HER2)-positive, early-stage breast cancer who survive without cancer recurrence. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 3, 2018 Category: International Medicine & Public Health Source Type: news

Will Immunotherapy Be a PANACEA for Breast Cancer? Will Immunotherapy Be a PANACEA for Breast Cancer?
Drs Kathy Miller and Sherene Loi discuss advances in immunotherapy for breast cancer, particularly in HER2-positive disease and TNBC.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 2, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Ganetespib, Paclitaxel, Trastuzumab for HER2+ Breast Cancer Ganetespib, Paclitaxel, Trastuzumab for HER2+ Breast Cancer
Early research finds that ganetespib added to paclitaxel and trastuzumab shows promise for heavily pretreated patients with HER2+ breast cancer.Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 2, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

For Low-Level HER2 Breast Cancer, Trastuzumab Is a No-Go For Low-Level HER2 Breast Cancer, Trastuzumab Is a No-Go
Although the study didn't turn out as hoped, NSABP B-47 will help inform the decision of whether patients with low-level HER2 breast cancer should receive trastuzumab.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 29, 2017 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Mylan breast cancer drug approved in Brazil
Mylan NV on Friday said it had received the green light in Brazil for a treatment for breast cancer that it developed with a partner in the country. Biocon LTD (BSE: BIOCON) and Mylan (Nasdaq: MYL) co-developed biosimilar Trastuzumab, which treats overexpressing HER2-positive metastatic breast cancer, HER2-positive early stage breast cancer and HER2-positive advanced gastric cancer. It will be sold in Brazil in Brazil as Zedora by Libbs Farmac eutica. "The approval of Zedora, Brazil's first Trastuzumab… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 29, 2017 Category: Pharmaceuticals Authors: Paul J. Gough Source Type: news

Triple Therapy Improves PFS in Certain Breast Ca Patients (CME/CE)
(MedPage Today) -- Dual HER2 blockade combined with aromatase inhibitor shows benefit (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 28, 2017 Category: Hematology Source Type: news

FDA approves Roche ’s Perjeta (pertuzumab) for adjuvant treatment of specific type of early breast cancer
Roche today announced the US Food and Drug Administration (FDA) has approved Perjeta ® (pertuzumab), in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen), for adjuvant (after surgery) treatment of HER2-positive early breast cancer (eBC) at high risk of recurrence. (Source: Roche Media News)
Source: Roche Media News - December 21, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Perjeta (pertuzumab) for adjuvant treatment of specific type of early breast cancer
Roche today announced the US Food and Drug Administration (FDA) has approved Perjeta ® (pertuzumab), in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen), for adjuvant (after surgery) treatment of HER2-positive early breast cancer (eBC) at high risk of recurrence. (Source: Roche Investor Update)
Source: Roche Investor Update - December 21, 2017 Category: Pharmaceuticals Source Type: news

Lapatinib With Foretinib in HER2+ Metastatic Breast Cancer Lapatinib With Foretinib in HER2+ Metastatic Breast Cancer
Early research finds limited activity with the combination of lapatinib and foretinib for advanced HER2+ breast cancer.Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 18, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Aspirin, NSAIDs and Prospective Risk of HER2+ Breast Cancer Aspirin, NSAIDs and Prospective Risk of HER2+ Breast Cancer
Does aspirin or ibuprofen reduce risk of HER2+ breast cancer?Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 15, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Everolimus With Trastuzumab and Paclitaxel for HER2+ MBC Everolimus With Trastuzumab and Paclitaxel for HER2+ MBC
Is the combination of everolimus, trastuzumab, and paclitaxel as safe in Asian patients as it is in the overall population?Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 13, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

PARP inhibitor improves progression-free survival in patients with advanced breast cancers and BRCA
(University of Texas M. D. Anderson Cancer Center) In a randomized, Phase III trial led by researchers at the University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 8, 2017 Category: Cancer & Oncology Source Type: news

Ribociclib Effective in Younger Breast Cancer Patients Too Ribociclib Effective in Younger Breast Cancer Patients Too
In premenopausal women with HR-positive, HER2-negative advanced breast cancer, the CDK4/6 inhibitor plus endocrine therapy dramatically improves progression-free survival compared with endocrine therapy alone.Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 8, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Biological factors don't fully explain racial disparities for breast cancer type
(UNC Lineberger Comprehensive Cancer Center) The biological features of patients' tumors partially explained a racial disparity for women with hormone receptor-positive, HER2-negative breast cancer, but UNC Lineberger Comprehensive Cancer Center researchers said it didn't explain it completely. The preliminary findings were reported at the 2017 San Antonio Breast Cancer Symposium. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 7, 2017 Category: International Medicine & Public Health Source Type: news